Trials / Withdrawn
WithdrawnNCT03355170
Cardiac Safety of Lansoprazole and Domperidon Combination
Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Lansoprazole/Domperidone | Experimental |
| DRUG | Lansoprazole | Active comparator |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2018-12-01
- Completion
- 2019-01-01
- First posted
- 2017-11-28
- Last updated
- 2023-01-05
Locations
16 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03355170. Inclusion in this directory is not an endorsement.